JPMorgan Chase & Co. Buys 1,026,939 Shares of Haleon plc (NYSE:HLN)

JPMorgan Chase & Co. boosted its holdings in Haleon plc (NYSE:HLN - Free Report) by 25.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,084,202 shares of the company's stock after purchasing an additional 1,026,939 shares during the period. JPMorgan Chase & Co. owned about 0.11% of Haleon worth $53,791,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Fortitude Family Office LLC bought a new position in shares of Haleon in the 3rd quarter valued at about $28,000. Toronto Dominion Bank boosted its position in Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock valued at $38,000 after purchasing an additional 3,470 shares during the last quarter. Prospera Private Wealth LLC bought a new position in Haleon in the third quarter valued at approximately $57,000. BOKF NA increased its position in shares of Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company's stock worth $58,000 after purchasing an additional 2,842 shares during the last quarter. Finally, Brown Brothers Harriman & Co. raised its stake in shares of Haleon by 21.4% during the 2nd quarter. Brown Brothers Harriman & Co. now owns 7,569 shares of the company's stock worth $63,000 after purchasing an additional 1,334 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on HLN shares. Morgan Stanley boosted their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a report on Friday, September 20th. UBS Group upgraded shares of Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Haleon has a consensus rating of "Buy" and a consensus target price of $10.95.

Haleon Stock Performance

Shares of HLN stock traded up $0.02 during trading on Friday, reaching $9.46. 4,643,971 shares of the company's stock were exchanged, compared to its average volume of 4,714,035. The firm's fifty day moving average price is $9.64 and its 200-day moving average price is $9.66. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The stock has a market capitalization of $42.82 billion, a PE ratio of 27.82, a PEG ratio of 2.95 and a beta of 0.28. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.